Jiwon Oh, MD, PhD, FRCPC - New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now

Go online to PeerView.com/JHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent research and improved understanding of the pathogenesis of multiple sclerosis (MS) has led to the development of multiple biomarkers and imaging modalities that can improve clinicians’ ability to individualize therapy through more effective monitoring of disease progression and treatment response. The promise of eventually arriving at data-driven personalized care—coupled with the number of available and emerging therapies for MS treatment—makes it more important than ever that clinicians remain up-to-date on advances in biomarkers and imaging approaches, as well as shared decision-making strategies. In this activity, based on a recent live symposium, MS experts cover the latest data on these new and emerging biomarkers for MS management. Using examples from their own practice, the panelists also discuss ways to incorporate these biomarker findings into individualized treatment decisions to empower patients and improve treatment outcomes. Upon completion of this activity, participants should be better able to: Describe emerging biomarkers that may play a role in evaluating MS disease activity, progression, and treatment response; Individualize treatment decisions for patients with MS, incorporating biomarker findings, disease status, and other patient-specific characteristics; and Integrate team-based shared decision-making strategies to facilitate appropriate treatment selection, empower patients, and improve outcomes